MARKET

VYGR

VYGR

Voyager Therapeutics Inc
NASDAQ
7.57
-0.08
-1.05%
Closed 16:55 04/24 EDT
OPEN
7.65
PREV CLOSE
7.65
HIGH
7.66
LOW
7.45
VOLUME
312.90K
TURNOVER
0
52 WEEK HIGH
14.34
52 WEEK LOW
6.06
MARKET CAP
411.06M
P/E (TTM)
2.550
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at VYGR last week (0415-0419)?
Weekly Report · 3d ago
Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Voyager Therapeutics (NASDAQ:VYGR) has a return on equity of 56% . The ROE is a measure of how much profit a company can generate from its earnings. The company earned 56% in the last year. This is a high rate of return, even compared to the industry average of 16%. Voyager Therapeutic has a good ROE, but its share price is down 14%. The company has an impressive earnings growth rate of 44% over the last five years. Check out the booming earnings growth of VoyagerTherapeutics       
Simply Wall St · 04/17 11:30
Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships
TipRanks · 04/17 09:07
VOYAGER THERAPEUTICS INC: EXPECT TO FILE AN INVESTIGATIONAL NEW DRUG (IND) APPLICATION WITH FDA FOR PROGRAM IN 2025
Reuters · 04/16 11:00
VOYAGER THERAPEUTICS ANNOUNCES SELECTION OF DEVELOPMENT CANDIDATE FOR GBA1 PROGRAM IN COLLABORATION WITH NEUROCRINE BIOSCIENCES, TRIGGERING MILESTONE PAYMENT
Reuters · 04/16 11:00
VOYAGER THERAPEUTICS:ELIGIBLE TO RECEIVE ADDITIONAL FUTURE DEVELOPMENT & COMMERCIALIZATION MILESTONE PAYMENTS BASED ON FURTHER ADVANCEMENT OF PROGRAM
Reuters · 04/16 11:00
Weekly Report: what happened at VYGR last week (0408-0412)?
Weekly Report · 04/15 09:18
Weekly Report: what happened at VYGR last week (0401-0405)?
Weekly Report · 04/08 09:19
More
About VYGR
Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Webull offers Voyager Therapeutics Inc stock information, including NASDAQ: VYGR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VYGR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VYGR stock methods without spending real money on the virtual paper trading platform.